INTRODUCTION: Treatment with antidepressants and antipsychotics, though effective, is unspecific as agents that differ greatly in their biochemical and pharmacological actions have virtually the same efficacy. Half of the patients with initial improvement show incomplete response, while a large proportion of patients exhibit a refractory clinical picture which is resistant to all treatment modalities. METHODS: Our analyses were based on a reference study of 2,848 depressive inpatients under monotherapeutic treatment with 7 different antidepressants or placebo, along with a naturalistic study of depressive and schizophrenic patients (296 inpatients, 363 outpatients) under today's "standard" polypharmaceutic treatment regimens. RESULTS: The empirical data suggested the following predictors of response: (1) severity at baseline, (2) early onset of improvement, (3) unwanted side-effects, and (4) medical comorbidity. A combination of these predictors with Therapeutic Drug Monitoring (TDM) methods has direct clinical relevance. DISCUSSION: Evidence-based approaches to personalized treatment help improving the unsatisfactory situation patients and clinicians are faced with, given today's incomplete treatments and the fact that the mechanisms by which antidepressants and antipsychotics ultimately exert their therapeutic effects are only marginally understood. Georg Thieme Verlag KG Stuttgart · New York.
INTRODUCTION: Treatment with antidepressants and antipsychotics, though effective, is unspecific as agents that differ greatly in their biochemical and pharmacological actions have virtually the same efficacy. Half of the patients with initial improvement show incomplete response, while a large proportion of patients exhibit a refractory clinical picture which is resistant to all treatment modalities. METHODS: Our analyses were based on a reference study of 2,848 depressive inpatients under monotherapeutic treatment with 7 different antidepressants or placebo, along with a naturalistic study of depressive and schizophrenicpatients (296 inpatients, 363 outpatients) under today's "standard" polypharmaceutic treatment regimens. RESULTS: The empirical data suggested the following predictors of response: (1) severity at baseline, (2) early onset of improvement, (3) unwanted side-effects, and (4) medical comorbidity. A combination of these predictors with Therapeutic Drug Monitoring (TDM) methods has direct clinical relevance. DISCUSSION: Evidence-based approaches to personalized treatment help improving the unsatisfactory situation patients and clinicians are faced with, given today's incomplete treatments and the fact that the mechanisms by which antidepressants and antipsychotics ultimately exert their therapeutic effects are only marginally understood. Georg Thieme Verlag KG Stuttgart · New York.
Authors: J M Biernacka; K Sangkuhl; G Jenkins; R M Whaley; P Barman; A Batzler; R B Altman; V Arolt; J Brockmöller; C H Chen; K Domschke; D K Hall-Flavin; C J Hong; A Illi; Y Ji; O Kampman; T Kinoshita; E Leinonen; Y J Liou; T Mushiroda; S Nonen; M K Skime; L Wang; B T Baune; M Kato; Y L Liu; V Praphanphoj; J C Stingl; S J Tsai; M Kubo; T E Klein; R Weinshilboum Journal: Transl Psychiatry Date: 2015-04-21 Impact factor: 6.222
Authors: Roger S McIntyre; Philip Gorwood; Michael E Thase; Charlie Liss; Dhaval Desai; Ji Chen; Michael Bauer Journal: J Clin Psychopharmacol Date: 2015-12 Impact factor: 3.153
Authors: H H Stassen; S Bachmann; R Bridler; K Cattapan; D Herzig; A Schneeberger; E Seifritz Journal: Eur Arch Psychiatry Clin Neurosci Date: 2020-07-21 Impact factor: 5.270